• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
HE Hua, ZHANG Xue, WANG Yuhao, LIU Xiaoquan. Advances in pharmacokinetic and pharmacodynamic modeling of monoclonal antibody[J]. Journal of China Pharmaceutical University, 2015, 46(3): 279-288. DOI: 10.11665/j.issn.1000-5048.20150304
Citation: HE Hua, ZHANG Xue, WANG Yuhao, LIU Xiaoquan. Advances in pharmacokinetic and pharmacodynamic modeling of monoclonal antibody[J]. Journal of China Pharmaceutical University, 2015, 46(3): 279-288. DOI: 10.11665/j.issn.1000-5048.20150304
shu

Advances in pharmacokinetic and pharmacodynamic modeling of monoclonal antibody

More Information
    Graphical Abstract
    • Abstract
  • The successes of therapeutic monoclonal antibodies(mAbs)in clinical practice has drawn more attention to mAbs development. Compared to chemical drugs with small molecules, mAbs have larger molecular weight; besides, they show much higher selectivity and specificity. As a result, new pharmacokinetic(PK)and pharmacokinetic/pharmacodynamic(PK/PD)models have been proposed to guide mAbs development. This article summarizes the unique PK characteristics of mAbs and introduces the models used in PK investigation of mAbs, such as target-mediated drug disposition(TMDD)model and physiologically based pharmacokinetic(PBPK)model. In addition, four different categories of PK/PD models for mAbs in immuno-toxicotherapy, target-cell elimination, alteration of cellular function and drug targeting are also reviewed in the present article.
    • FullText(HTML)
    • References (36)
  • [1]
    Emmons C,Hunsicker LG.Muromonab-CD3(Orthoclone OKT3):the first monoclonal antibody approved for therapeutic use[J].Iowa Med,1987,77(2):78-82.
    [2]
    Gómez-Mantilla JD, Trocóniz IF, Parra-Guillén Z, et al. Review on modeling anti-antibody responses to monoclonal antibodies[J].J Pharmacokinet Pharmacodyn,2014,41(5):523-536.
    [3]
    Buss NA,Henderson SJ,McFarlane M,et al.Monoclonal antibody therapeutics:history and future[J].Curr Opin Pharmacol,2012,12(5):615-622.
    [4]
    Wang W,Wang EQ,Balthasar JP.Monoclonal antibody pharmacokinetics and pharmacodynamics[J].Clin Pharmacol Ther,2008,84(5):548-558.
    [5]
    Dostalek M,Gardner I,Gurbaxani BM,et al.Pharmacokinetics,pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies[J].Clin Pharmacokinet,2013,52(2):83-124.
    [6]
    Richter WF,Bhansali SG,Morris ME.Mechanistic determinants of biotherapeutics absorption following SC administration[J].AAPS J,2012,14(3):559-570.
    [7]
    Supersaxo A,Hein WR,Steffen H.Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration[J].Pharm Res,1990,7(2):167-169.
    [8]
    Porter CJ,Edwards GA,Charman SA.Lymphatic transport of proteins after s.c.injection:implications of animal model selection[J].Adv Drug Deliver Rev,2001,50(1/2):157-171.
    [9]
    Lobo ED,Hansen RJ,Balthasar JP.Antibody pharmacokinetics and pharmacodynamics[J].J Pharm Sci,2004,93(11):2645-2668.
    [10]
    Zhao L,Shang EY,Sahajwalla CG.Application of pharmacokinetics-pharmacodynamics/clinical response modeling and simulation for biologics drug development[J].J Pharm Sci,2012,101(12):4367-4382.
    [11]
    Yokota T,Milenic DE,Whitlow M,et al.Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms[J].Cancer Res,1992,52(12):3402-3408.
    [12]
    Ghetie V,Popov S,Borvak J,et al.Increasing the serum persistence of an IgG fragment by random mutagenesis[J].Nat Biotechnol,1997,15(7):637-640.
    [13]
    Dall′Acqua WF,Woods RM,Ward ES,et al.Increasing the affinity of a human IgG1 for the neonatal Fc receptor:biological consequences[J].J Immunol,2002,169(9):5171-5180.
    [14]
    Weisman MH,Moreland LW,Furst DE,et al.Efficacy,pharmacokinetic,and safety assessment of adalimumab,a fully human anti-tumor necrosis factor-alpha monoclonal antibody,in adults with rheumatoid arthritis receiving concomitant methotrexate:a pilot study[J].Clin Ther,2003,25(6):1700-1721.
    [15]
    Gibiansky L,Gibiansky E.Target-mediated drug disposition model:approximations,identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics[J].Expert Opin Drug Met,2009,5(7):803-812.
    [16]
    de Vries MK, Brouwer E, van der Horst-Bruinsma IE, et al.Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation[J].Ann Rheum Dis,2009,68(11):1787-1788.
    [17]
    Schellekens H.Immunogenicity of therapeutic proteins:clinical implications and future prospects[J].Clin Ther,2002,24(11):1720-1740.
    [18]
    Stephens S,Emtage S,Vetterlein O,et al.Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic responses[J].Immunology,1995,85(4):668-674.
    [19]
    Svenson M,Geborek P,Saxne T,et al.Monitoring patients treated with anti-TNF-alpha biopharmaceuticals:assessing serum infliximab and antiinfliximab antibodies[J].Rheumatology,2007,46(12):1828-1834.
    [20]
    Rehlaender BN,Cho MJ.Antibodies as carrier proteins[J].Pharm Res,1998,15(11):1652-1656.
    [21]
    Kairemo KJ,Lappalainen AK,Kaapa E,et al.In vivo detection of intervertebral disk injury using a radiolabeled monoclonal antibody against keratan sulfate[J].J Nucl Med,2001,42(3):476-482.
    [22]
    Danilov SM,Gavrilyuk VD,Franke FE,et al.Lung uptake of antibodies to endothelial antigens:key determinants of vascular immunotargeting[J].Am J Physiol-Lung C,2001,280(6):L1335-L1347.
    [23]
    Levy G.Pharmacologic target-mediated drug disposition[J].Clin Pharmacol Ther,1994,56(3):248-252.
    [24]
    Mager DE,Jusko WJ.General pharmacokinetic model for drugs exhibiting target-mediated drug disposition[J].J Pharmacokinet Pharmacodyn,2001,28(6):507-532.
    [25]
    Mager DE,Krzyzanski W.Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition[J].Pharm Res,2005,22(10):1589-1596.
    [26]
    Gibiansky L,Gibiansky E,Kakkar T,et al.Approximations of the target-mediated drug disposition model and identifiability of model parameters[J].J Pharmacokinet Pharmacodyn,2008,35(5):573-591.
    [27]
    Davda JP,Jain M,Batra SK,et al.A physiologically based pharmacokinetic(PBPK)model to characterize and predict the disposition of monoclonal antibody CC49 and its single chain Fv constructs[J].Int Immunopharmacol,2008, 8(3):401-413.
    [28]
    Covell DG,Barbet J,Holton OD,et al.Pharmacokinetics of monoclonal immunoglobulin G1,F(ab′)2,and Fab′ in mice[J].Cancer Res,1986,46(8):3969-3978.
    [29]
    Baxter LT,Zhu H,Mackensen DG,et al.Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice[J].Cancer Res,1994,54(6):1517-1528.
    [30]
    Baxter LT,Zhu H,Mackensen DG,et al.Biodistribution of monoclonal antibodies:scale-up from mouse to human using a physiologically based pharmacokinetic model[J].Cancer Res,1995,55(20):4611-4622.
    [31]
    Hansen RJ, Balthasar JP. Pharmacokinetic/pharmacodynamics modeling of the effects of intravenous immunoglobulin on the disposition of antiplatelet antibodies in a rat model of immune thrombocytopenia[J].J Pharm Sci,2003,92(6):1206-1215.
    [32]
    Shah DK,Betts AM.Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human[J].J Pharmacokinet Pharmacodyn,2012,39(1):67-86.
    [33]
    Fetterly GJ,Aras U,Meholick PD,et al.Utilizing pharmacokinetics/pharmacodynamics modeling to simultaneously examine free CCL2,total CCL2 and carlumab(CNTO 888)concentration time data[J].J Clin Pharmacol,2013,53(10):1020-1027.
    [34]
    Sharma A,Davis CB,Tobia LA,et al.Comparative pharmacodynamics of keliximab and clenoliximab in transgenic mice bearing human CD4[J].J Pharmacol Exp Ther,2000,293(1):33-41.
    [35]
    Ng CM,Joshi A,Dedrick RL,et al.Pharmacokinetic-pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis[J].Pharm Res,2005,22(7):1088-1100.
    [36]
    Shah DK,Haddish-Berhane N,Betts A.Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model:a case study with brentuximab-vedotin[J].J Pharmacokinet Pharm,2012,39(6):643-659.
    • Related Articles

  • Related Articles

    [1]WU Xufeng, CHAI Shiying, LIU Jianhong, WANG Zhihui, YIN Ruifeng, CAO Ruiwei, SUN Xinqiang. Improvement of synthetic route of brivudine[J]. Journal of China Pharmaceutical University, 2022, 53(1): 41-45. DOI: 10.11665/j.issn.1000-5048.20220106
    [2]WANG Dong, ZHONG Jian, WANG Ling, ZHOU Zhihui, JIANG Haiting, LUO Peng, WANG Xizhi, WANG Chongyi. Improved synthetic process of apremilast[J]. Journal of China Pharmaceutical University, 2021, 52(5): 536-540. DOI: 10.11665/j.issn.1000-5048.20210504
    [3]HAN Chengqun, ZOU Qiaogen, SUN Qian, XIA Yunyan. Improvement of synthesis process of mirabegron[J]. Journal of China Pharmaceutical University, 2020, 51(4): 449-453. DOI: 10.11665/j.issn.1000-5048.20200409
    [4]ZHANG Qiuyue, YOU Qidong, YANG Jinpeng. Process improvement on the synthesis of atomoxetine[J]. Journal of China Pharmaceutical University, 2019, 50(4): 405-409. DOI: 10.11665/j.issn.1000-5048.20190404
    [5]LIU Li, WANG Chen, LIU Lixin, JI Tingting. Improved synthesis of analgesic pentazocine[J]. Journal of China Pharmaceutical University, 2018, 49(5): 568-571. DOI: 10.11665/j.issn.1000-5048.20180508
    [6]CHEN Suting, CHEN Song, GAO Xiangdong. Construction, expression, purification and neuroprotective activity of TAT-FGF21 fusion protein[J]. Journal of China Pharmaceutical University, 2018, 49(4): 496-501. DOI: 10.11665/j.issn.1000-5048.20180417
    [7]WEI Qingjie, QIAO Junhua, CHEN Jianjun, GAO Zhigang, LI Yaqing. An improvement for synthesis of ceftriaxone sodium[J]. Journal of China Pharmaceutical University, 2016, 47(2): 163-165. DOI: 10.11665/j.issn.1000-5048.20160206
    [8]WU Jiaquan, ZHOU Ping, LIU Yang, JIE Chuanming, CAO Huanyan, PENG Tao, LI Xiaohong, ZHANG Haijun. An improved preparing process for rivastigmine[J]. Journal of China Pharmaceutical University, 2015, 46(4): 421-425. DOI: 10.11665/j.issn.1000-5048.20150406
    [9]Effects of Hypericin on Behavior and Proliferation of Ependymocytes and Subependymocytes of Rat with Olfactory Bulb Impairment[J]. Journal of China Pharmaceutical University, 2004, (2): 48-52.
    [10]Effects of Hypericin on Behavior and Expression of 5-HT and NE in Brain of Depression Rat with Chronic Stress[J]. Journal of China Pharmaceutical University, 2003, (1): 72-75.

Catalog

    Get Citation
    XML
    Article views (2463) PDF downloads (5676) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：290198

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return